Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
10.87
+0.32 (3.08%)
Sep 14, 2026, 3:11 PM EDT - Market open
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
831.76M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| Geron | 204.56M |
| Crescent Biopharma | 11.88M |
| Aclaris Therapeutics | 8.22M |
| Silence Therapeutics | 615.00K |
| Avalo Therapeutics | 59.00K |
CADL News
- 4 days ago - Candel Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 days ago - Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - GlobeNewsWire
- 12 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Candel Therapeutics to Present at September Investor Conferences - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics price target raised to $12 from $9 at BofA - TheFly
- 4 weeks ago - Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Candel Therapeutics Quarterly report: Q2 2026 - Filings